Founders

Rolf Zinkernagel

Born and raised in Basel, Rolf Zinkernagel studied at the Medical School of the University of Basel, obtaining his MD degree in 1968, and graduating to become a surgeon. In the Institute of Biochemistry of Lausanne he worked on immunity against infections.  From 1973-75 at the Australian National University, Canberra, he made seminal observations with Peter Doherty on how cytotoxic T cells recognize virus infected cells in an infected host (Nobel Prize for Physiology or Medicine 1996). He moved to the Scripps Clinic and Research Foundation in La Jolla, USA from 1975 to 1979, where he studied T cell maturation and development of the T cell repertoire, which is dependent on transplantation antigen expression in the thymus. In 1980 he joined the Department of Pathology, University of Zurich, as an Associate Professor where, together with Hans Hengartner, he has been studying immune protection and immunopathology caused by virus infections. He retired from the University in Spring 2008.

Andreas Bergthaler

Andreas Bergthaler studied veterinary medicine in Vienna followed by graduate and postgraduate research with Hans Hengartner and Rolf Zinkernagel at the University/ETH of Zurich and with Daniel Pinschewer at the University of Geneva in Switzerland. As a postdoctoral fellow he subsequently joined the laboratory of Alan Aderem at the Institute for Systems Biology in Seattle, USA. In 2011, he established his research group at the  Research Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences. The Bergthaler laboratory pursues an integrative approach comprising infection models and tools of immunology, pathology and systems biology in order to dissect novel disease-relevant interactions between pathogens and the host. Systemic perspectives at the organism and organ level address fundamental questions of infection biology and contribute to revealing the molecular origins of virus-induced immunopathologies and other inflammatory diseases.

Lukas Flatz

Lukas Flatz is currently Senior Consultant at the Clinic for Dermatology and Group Leader at the Institute of Immunobiology, Kantonsspital St. Gallen, in St. Gallen, Switzerland. He studied at the medical school of the University of Berne and received both a Swiss medical degree and a medical doctorate in Berne. He was a member of the Swiss Board of exams in Dermatology and brings significant experience through his work at medical institutions. He co-founded ArenaVax AG and Hookipa Biotech AG and was awarded the Pfizer Prize in 2011, the Leenaards Junior Clinical Scientist in 2012, the Medic Prize in 2013 and the Swiss Skin Cancer Award in 2014. Lukas is also co-author of more than 25 publications and has reviewed a number of book chapters and case reports.

Daniel Pinschewer

Daniel Pinschewer is founder and Chief Scientific Officer (CSO) of Hookipa and is responsible for enhancing Hookipa’s research capabilities. After graduating from the University of Zurich Medical School in 2000, he became a postdoctoral researcher. He specialized in molecular virology, working alongside Juan Carlos de la Torre (The Scripps Research Institute, USA), and in immunology with Rolf Zinkernagel and Hans Hengartner (University of Zurich, Switzerland). In 2007, he was appointed Associate Professor of Immunology at the University of Geneva Medical School and, in 2013, was recruited to the University of Basel, where he continues to serve as a Professor of Virology. Throughout his career he has been recognised for his contributions to the scientific community, including receiving awards from the European Research Council (ERC starting grant) and from the Swiss National Science Foundation (stipendiary professorship). National and international honors include; the Georges-Köhler-Prize of the German Society for Immunology, the Loeffler-Frosch-Prize of the Society for Virology, the Debiopharm Group Life Sciences Award, the Pfizer Research Prize, and the Prix Leenaards. Daniel’s research discoveries have formed the technological foundation on which Hookipa is founded.